We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

256 hedge funds and large institutions have $5.32B invested in IVERIC bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 106 funds opening new positions, 58 increasing their positions, 69 reducing their positions, and 73 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more funds holding in top 10

Funds holding in top 10: 1540 (+25)

129% more call options, than puts

Call options by funds: $538M | Put options by funds: $234M

49% more capital invested

Capital invested by funds: $3.58B → $5.32B (+$1.74B)

45% more first-time investments, than exits

New positions opened: 106 | Existing positions closed: 73

15% more funds holding

Funds holding: 223256 (+33)

16% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 69

Holders
256
Holders Change
+33
Holders Change %
+14.8%
% of All Funds
4.02%
Holding in Top 10
40
Holding in Top 10 Change
+25
Holding in Top 10 Change %
+166.67%
% of All Funds
0.63%
New
106
Increased
58
Reduced
69
Closed
73
Calls
$538M
Puts
$234M
Net Calls
+$303M
Net Calls Change
+$293M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$538M +$608K +17,227 +0.1%
BlackRock
2
BlackRock
New York
$424M +$23.3M +661,051 +7%
ACA
3
Avoro Capital Advisors
New York
$317M +$44.1M +1,250,000 +18%
UOC
4
UBS O'Connor
Illinois
$230M +$206M +5,850,120 New
BCM
5
Beryl Capital Management
California
$210M +$188M +5,339,518 New
State Street
6
State Street
Massachusetts
$184M -$33.4M -946,285 -17%
Goldman Sachs
7
Goldman Sachs
New York
$166M +$114M +3,225,818 +324%
Millennium Management
8
Millennium Management
New York
$156M +$96M +2,719,573 +219%
Deutsche Bank
9
Deutsche Bank
Germany
$126M +$67.4M +1,910,414 +149%
TAL
10
TIG Advisors LLC
New York
$114M +$103M +2,904,364 New
Fidelity International
11
Fidelity International
Bermuda
$112M +$100M +2,841,000 New
AAM
12
Alpine Associates Management
Florida
$106M +$95M +2,692,538 New
KC
13
Kryger Capital
United Kingdom
$99.3M +$89.1M +2,523,853 New
TCM
14
TCG Crossover Management
California
$96.3M -$95M -2,692,289 -52%
FCM
15
Farallon Capital Management
California
$96.1M +$69.1M +1,957,500 +404%
LP
16
LMR Partners
United Kingdom
$79.6M +$71.4M +2,023,659 New
HI
17
HBK Investments
Texas
$78.7M +$70.6M +2,000,000 New
AllianceBernstein
18
AllianceBernstein
Tennessee
$77.5M -$74M -2,096,250 -52%
Morgan Stanley
19
Morgan Stanley
New York
$70.5M +$33.9M +960,943 +116%
SFM
20
Soros Fund Management
New York
$66.9M +$60M +1,700,001 New
WCMNY
21
Westchester Capital Management (New York)
New York
$66.3M +$59.5M +1,685,423 New
MF
22
Magnetar Financial
Illinois
$65.6M +$58.9M +1,668,239 New
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
23
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$65.3M +$58.6M +1,658,800 New
Bank of America
24
Bank of America
North Carolina
$64.4M +$36.2M +1,024,205 +167%
Man Group
25
Man Group
United Kingdom
$54.1M +$48.5M +1,374,470 New

ISEE Hedge Fund Activity: Q2 2023 in Review

256 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2023, worth a combined $5.32B — up 49% from $3.58B a quarter earlier.

Buyers outnumbered sellers: 106 funds opened new ISEE positions and 73 closed out — a net gain of 33 holders — while 58 added to existing stakes and 69 trimmed.

The largest buyer was UBS O'Connor, opening a new position worth an estimated $206M. The largest seller was T. Rowe Price Associates, cutting an estimated $238M.

  • 256 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2023, up from 223 in Q1 2023.
  • Funds reported $5.32B of IVERIC bio, Inc. Common Stock stock for Q2 2023, up 49% quarter-over-quarter.
  • 106 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2023 and 73 closed out, a net change of +33 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q2 2023 was UBS O'Connor, an estimated $206M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q2 2023 was T. Rowe Price Associates, an estimated $238M sold.

Based on aggregated 13F filings for Q2 2023.